BB-1701 has survived Eisai’s decision not to option the HER2-directed antibody-drug conjugate. | BB-1701 has survived Eisai’s ...
the National Institute for Care and Health Excellence (Nice), to reject AstraZeneca’s Enhertu drug for breast cancer. The treatment has been found to double the life expectancy for terminal ...
Called Enhertu, it is the first licensed targeted ... and has been shown to lengthen a patient’s life span for much longer than traditional treatments such as chemotherapy.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback